1. 2000
2. Cyhoeddwyd

   The influence of non-compliance on the effectiveness and cost-effectiveness of drug therapies

   Hughes, D., Hughes, D. A., Bagust, A., Haycox, A. & Walley, T., 1 Ion 2000, Yn: Value in Health. 3, 5, t. 373

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

3. Cyhoeddwyd

   Pragmatic trials - design features and implications for clinical decision making

   Hughes, D., Urdahl, H., Hughes, D. A. & Freemantle, N., 1 Awst 2000.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

4. Cyhoeddwyd

   The influence of non-compliance on the effectiveness and cost-effectiveness of drug therapies

   Hughes, D., Hughes, D. A., Bagust, A., Haycox, A. & Walley, T., 1 Tach 2000.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

5. 2001
6. Cyhoeddwyd

   A review of economic models for second-line chemotherapy in the management of advanced, metastatic breast cancer.

   Hughes, D. & Hughes, D. A., 1 Ion 2001, 2001 gol. Unknown.

   Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

7. Cyhoeddwyd

   Accounting for non-compliance in pharmacoeconomic evaluations.

   Hughes, D., Hughes, D. A., Bagust, A., Haycox, A. & Walley, T., 1 Ion 2001, Yn: Pharmacoeconomics. 19, 12, t. 1185-1197

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

8. Cyhoeddwyd

   Economic evaluations during early (Phase II) drug development: A role for clinical trial simulations.

   Hughes, D., Hughes, D. A. & Walley, T., 1 Ion 2001, Yn: Pharmacoeconomics. 19, 11, t. 1069-1077

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

9. Cyhoeddwyd

   Pharmacokinetic-Pharmacodynamic modelling of Lapdap (CPG-DDS) combination.

   Hughes, D., Hughes, D. A., Watkins, B. & Winstanley, P., 1 Ion 2001, 2001 gol. Unknown.

   Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

10. Cyhoeddwyd

    The influence of non-compliance on the effectiveness and cost-effectiveness of drug therapies.

    Hughes, D. & Hughes, D. A., 1 Ion 2001, 2001 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

11. Cyhoeddwyd

    Impact of non-compliance on the cost-effectiveness of statin therapy

    Hughes, D., Hughes, D. A. & Bagust, A., 1 Medi 2001, Yn: Value in Health. 4, 6, t. 489

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

12. Cyhoeddwyd

    Pharmacometric analysis of duration of drug action: implications for improved forgiveness to medication non-compliance

    Hughes, D., Hughes, D. A. & Walley, T., 1 Medi 2001.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

13. Cyhoeddwyd

    Patient compliance and pharmacoeconomics

    Hughes, D. & Hughes, D. A., 1 Hyd 2001.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

14. Cyhoeddwyd

    The impact of non-compliance on the cost-effectiveness of pharmaceuticals: A review of the literature.

    Hughes, D., Hughes, D. A., Bagust, A., Haycox, A. & Walley, T., 1 Hyd 2001, Yn: Health Economics. 10, 7, t. 601-615

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

15. Cyhoeddwyd

    Impact of non-compliance on the clinical and cost-effectiveness of statins

    Hughes, D. & Hughes, D. A., 1 Tach 2001.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

16. 2002
17. Cyhoeddwyd

    Impact of non-compliance on the therapeutic coverage of oxybutynin – comparison of once- and twice-daily oral formulations.

    Hughes, D. & Hughes, D. A., 1 Ion 2002, 2002 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

18. Cyhoeddwyd

    Impact of non-compliance on the therapeutic coverage of risperidone – comparison of long acting injectible with oral formulations.

    Hughes, D. & Hughes, D. A., 1 Ion 2002, 2002 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

19. Cyhoeddwyd

    From efficacy to cost-effectiveness: accounting for non-compliance in pharmacoeconomics

    Hughes, D. & Hughes, D. A., 1 Mai 2002.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

20. Cyhoeddwyd

    Economic impact of poor compliance with pharmaceuticals.

    Hughes, D. & Hughes, D. A., 1 Awst 2002, Yn: Expert Review of Pharmacoeconomics and Outcomes Research. 2, 4, t. 327-335

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

21. Cyhoeddwyd

    Accurate and practical dosing of African populations using a height, weight and age model designed for lapdap

    Hughes, D., Hughes, D. A. & Bagust, A., 1 Tach 2002.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

22. Cyhoeddwyd

    Economic evaluation during early (phase II) trials

    Hughes, D. & Hughes, D. A., 1 Tach 2002.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

23. Cyhoeddwyd

    Impact of non-compliance on the cost-effectiveness of pharmaceuticals

    Hughes, D. & Hughes, D. A., 1 Tach 2002.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

24. Cyhoeddwyd

    Patient compliance and pharmacoeconomics

    Hughes, D. & Hughes, D. A., 1 Tach 2002.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

25. Cyhoeddwyd

    The population pharmacokinetics of lapdap

    Hughes, D., Ward, S., Simpson, J., Aarons, L., Szwandt, S. & Hughes, D. A., 1 Tach 2002.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

26. 2003
27. Cyhoeddwyd

    Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

    Hughes, D. & Hughes, D. A., 1 Mai 2003.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

28. Cyhoeddwyd

    Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

    Hughes, D. & Hughes, D. A., 1 Meh 2003.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

29. Cyhoeddwyd

    Predicting "real world" effectiveness by integrating adherence with pharmacodynamic modelling.

    Hughes, D., Hughes, D. A. & Walley, T., 1 Gorff 2003, Yn: Clinical Pharmacology and Therapeutics. 74, 1, t. 1-8

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

30. Cyhoeddwyd

    Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

    Hughes, D., Hughes, D. A. & Pirmohamed, M., 1 Medi 2003.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

31. Cyhoeddwyd

    Modelling changes in first line antimalarial therapy

    Hughes, D. & Hughes, D. A., 1 Medi 2003.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

32. Cyhoeddwyd

    Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

    Hughes, D., Hughes, D. A. & Pirmohamed, M., 1 Tach 2003.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

33. Cyhoeddwyd

    Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

    Hughes, D., Hughes, D. A. & Pirmohamed, M., 1 Tach 2003, Yn: Value in Health. 6, 6, t. 749

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

34. Cyhoeddwyd

    Cost-utility analysis of on demand rabeprazole and esomeprazole for symptomatic gastro oesophageal reflux disease

    Hughes, D., Hughes, D. A. & Dubois, D., 1 Tach 2003, Yn: Value in Health. 6, 6, t. 613

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

35. Cyhoeddwyd

    Cost-utility analysis of on-demand rabeprazole and esomeprazole for non-erosive reflux disease

    Hughes, D. & Hughes, D. A., 1 Tach 2003.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

36. Cyhoeddwyd

    Cost-utility analysis of on-demand rabeprazole and esomeprazole for non-erosive reflux disease

    Hughes, D. & Hughes, D. A., 1 Tach 2003.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

37. Cyhoeddwyd

    Use of PK-PD modelling to predict the impact of non-compliance

    Hughes, D. & Hughes, D. A., 1 Tach 2003.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

38. Cyhoeddwyd

    Drug compliance and pharmaceconomics

    Hughes, D. & Hughes, D. A., 1 Rhag 2003.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

39. 2004
40. Cyhoeddwyd

    Approaches to pharmacoeconomic analysis

    Hughes, D., Hughes, D. A., Walley, T. (gol.), Haycox, A. (gol.), Boland, A. (gol.) & Breckenridge, A. (gol.), 1 Ion 2004, Pharmacoeconomics. 2004 gol. Adis International, t. 101-126

    Allbwn ymchwil: Pennod mewn Llyfr/Adroddiad/Trafodion Cynhadledd › Pennod

41. Cyhoeddwyd

    Clinical Pharmacology: Special safety considerations in drug development and pharmacovigilance.

    Hughes, D., Atuah, K. N., Hughes, D. A. & Pirmohamed, M., 1 Ion 2004, Yn: Drug Safety. 27, 8, t. 535-554

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

42. Cyhoeddwyd

    Cost-effectiveness analysis of extended-release formulations of oxybutynin and tolterodine for the management of urge incontinence.

    Hughes, D., Hughes, D. A. & Dubois, D., 1 Ion 2004, Yn: Pharmacoeconomics. 22, 16, t. 1047-1059

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

43. Cyhoeddwyd

    Internationalisation of cost-effectiveness model for on-demand use of proton pump inhibitors - Belgium.

    Hughes, D. & Hughes, D. A., 1 Ion 2004, 2004 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

44. Cyhoeddwyd

    Modelling in health economics

    Hughes, D., Hughes, D. A., Walley, T. (gol.), Haycox, A. (gol.), Boland, A. (gol.) & Breckenridge, A. (gol.), 1 Ion 2004, Pharmacoeconomics. 2004 gol. Adis International, t. 141-154

    Allbwn ymchwil: Pennod mewn Llyfr/Adroddiad/Trafodion Cynhadledd › Pennod

45. Cyhoeddwyd

    The future challenges

    Hughes, D., Hughes, D. A., Walley, T. (gol.), Haycox, A. (gol.), Boland, A. (gol.) & Breckenridge, A. (gol.), 1 Ion 2004, Pharmacoeconomics. 2004 gol. Adis International, t. 167-174

    Allbwn ymchwil: Pennod mewn Llyfr/Adroddiad/Trafodion Cynhadledd › Pennod

46. Cyhoeddwyd

    Pharmacoeconomics in Wales: functions of the all Wales medicines strategy group

    Hughes, D. & Hughes, D. A., 1 Ebr 2004.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

47. Cyhoeddwyd

    Pharmacoeconomics of pharmacogenetic testing: azathioprine

    Hughes, D., McAllister, R. & Hughes, D. A., 1 Ebr 2004.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

48. Cyhoeddwyd

    Patient compliance and persistence with prescribed medication: Measurement and health economic impact

    Hughes, D., Koncz, T., Hughes, D. A., Cleemput, I. & Annemans, L., 1 Mai 2004.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

49. Cyhoeddwyd

    Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity

    Hughes, D., Hughes, D. A., Vilar, F. J., Ward, C. C., Alfirevic, A., Park, B. K. & Pirmohamed, M., 1 Meh 2004, Yn: Pharmacogenetics. 14, 6, t. 335-342

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

50. Cyhoeddwyd

    Introduction to pharmaeconomics

    Hughes, D. & Hughes, D. A., 1 Gorff 2004.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

51. Cyhoeddwyd

    Pharmacoeconomic models that incorporate non-compliance

    Hughes, D. & Hughes, D. A., 1 Gorff 2004.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

52. Cyhoeddwyd

    Pharmacoeconomics appraisals by the all Wales medicines strategy group

    Hughes, D. & Hughes, D. A., 1 Gorff 2004.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

53. Cyhoeddwyd

    The difference between effectiveness and efficacy of antimalarial drugs in Kenya.

    Hughes, D., Amin, A. A., Hughes, D. A., Marsh, V., Abuya, T. O., Kokwaro, G. O., Winstanley, P. A., Ochala, S. A. & Snow, R. W., 1 Medi 2004, Yn: Tropical Medicine and International Health. 9, 9, t. 967-974

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

54. Cyhoeddwyd

    Economic evaluation of on-demand maintenance therapy with proton pump inhibitors in patients with symptomatic gastroesophageal reflux disease - a Monte-Carlo analysis for Italy

    Hughes, D., Hughes, D. A., Marchetti, M. & Colombo, G., 1 Hyd 2004.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

55. Cyhoeddwyd

    A single centre open phase IV study to evaluate the safety and tolerability of chlorproguanil-dapsone when dosed by defined height bands

    Hughes, D., Makanga, M., Winstanley, P. & Hughes, D. A., 1 Tach 2004.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

56. Cyhoeddwyd

    Cost minimization of on-demand maintenance therapy with proton pump inhibitors in nonerosive gastroesophageal reflux disease

    Hughes, D. & Hughes, D. A., 1 Tach 2004, Yn: Value in Health. 7, 6, t. 753

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

57. Cyhoeddwyd

    From efficacy to effectiveness and cost-effectiveness: modelling possibilities

    Hughes, D. & Hughes, D. A., 1 Tach 2004.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

58. Cyhoeddwyd

    HLA-B*5701 and abacavir hypersensitivity - Reply.

    Hughes, D., Hughes, D. A., Park, B. K. & Pirmohamed, M., 1 Tach 2004, Yn: Pharmacogenetics. 14, 11, t. 784

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

59. 2005
60. Cyhoeddwyd

    Economic analysis of on-demand maintenance therapy with proton pump inhibitors in patients with non-erosive reflux disease.

    Hughes, D., Hughes, D. A., Bodger, K., Bytzer, P., De Herdt, D. & Dubois, D., 1 Ion 2005, Yn: Pharmacoeconomics. 23, 10, t. 1031-1041

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

61. Cyhoeddwyd

    Improving Outcomes in Children and Young People with Cancer: Analysis of the Potential Economic Impact of the Guidance.

    Hughes, D., Linck, P., Tunnage, B., Hughes, D. A. & Edwards, R. T., 1 Ion 2005, 2005 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

62. Cyhoeddwyd

    Internationalisation of cost-effectiveness model for on-demand use of proton pump inhibitors - Sweden.

    Hughes, D. & Hughes, D. A., 1 Ion 2005, 2005 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

63. Cyhoeddwyd

    Welsh Health Economics Network (WHEN): Scoping Report.

    Hughes, D., Farr, A., O Ceilleachair, A., Cohen, D., Hughes, D. A. & Phillips, C., 1 Ion 2005, 2005 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

64. Cyhoeddwyd

    Cost minimization of on-demand maintenance therapy with proton pump inhibitors in nonerosive gastroesophageal reflux disease.

    Hughes, D., Hughes, D. A., Marchetti, M. & Colombo, G., 1 Chwef 2005, Yn: Expert Review of Pharmacoeconomics and Outcomes Research. 5, 1, t. 29-38

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

65. Cyhoeddwyd

    Empirical analysis of the relationship between dose and duration of drug action

    Hughes, D. & Hughes, D. A., 1 Meh 2005.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

66. Cyhoeddwyd

    Pharmacokinetics, patient compliance and pharmaeconomics

    Hughes, D. & Hughes, D. A., 1 Meh 2005.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

67. Cyhoeddwyd

    Cisplatin plus vinorelbine or gemcitabine in patients with advanced non-small cell lung cancer: Pharmacoeconomic considerations.

    Hughes, D. & Hughes, D. A., 1 Gorff 2005, Yn: European Journal of Cancer. 41, 11, t. 1655

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

68. Cyhoeddwyd

    Public funding of drugs for orphan diseases

    Hughes, D. & Hughes, D. A., 1 Gorff 2005.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

69. Cyhoeddwyd

    Drugs for exceptionally rare diseases: do they deserve special status for funding?

    Hughes, D., Tunnage, B. & Yeo, S. T., 1 Tach 2005, Yn: QJM - An International Journal of Medicine. 98, 11, t. 829-836

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

70. Cyhoeddwyd

    Incorporating measures of compliance and persistence in pharmacoeconomic evaluations

    Hughes, D., Hughes, D. A. & Cowell, W., 1 Tach 2005.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

71. Cyhoeddwyd

    Public funding of drugs for orphan diseases

    Hughes, D. & Hughes, D. A., 1 Tach 2005.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

72. Cyhoeddwyd

    Public funding of drugs for orphan diseases

    Hughes, D. & Hughes, D. A., 1 Tach 2005.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

73. Cyhoeddwyd

    Trends and influences on use of antidiabetic drugs in England, 1992-2003.

    Walley, T., Hughes, D. & Kendall, H., 1 Tach 2005, Yn: Pharmacoepidemiology and Drug Safety. 14, 11, t. 769-773

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

74. Cyhoeddwyd

    Public funding of drugs for orphan diseases

    Hughes, D. & Hughes, D. A., 11 Tach 2005, Yn: Value in Health. 8, 6, t. A192

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

75. 2006
76. Cyhoeddwyd

    Beyond registration: measuring the public health potential of new treatments for Malaria in Africa.

    Hughes, D., Lang, T., Hughes, D. A., Kanyok, T., Kengeya-Kayondo, J., Marsh, V., Haaland, A., Pirmohamed, M. & Winstanley, P., 1 Ion 2006, Yn: Lancet Infectious Diseases. 6, 1, t. 46-52

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

77. Cyhoeddwyd

    Health economic aspects of patient non-compliance

    Hughes, D., Hughes, D. A., Davies, M. (gol.) & Kermani, F. (gol.), 1 Ion 2006, Patient Compliance: Sweetening the Pill. 2006 gol. Gower Publishing, t. 23-40

    Allbwn ymchwil: Pennod mewn Llyfr/Adroddiad/Trafodion Cynhadledd › Pennod

78. Cyhoeddwyd

    Improving Outcomes for People with Brain and Other CNS Tumours: Analysis of the Potential Economic Impact of the Guidance.

    Hughes, D., Linck, P., Priedane, E., Hughes, D. A. & Edwards, R. T., 1 Ion 2006, 2006 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

79. Cyhoeddwyd

    Improving Outcomes for People with Sarcoma: Analysis of the Potential Economic Impact of the Guidance.

    Hughes, D., Linck, P., Hughes, D. A. & Edwards, R. T., 1 Ion 2006, 2006 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

80. Cyhoeddwyd

    Less is more: Medicines that require less frequent administration improve adherence, but are they better?

    Hughes, D. & Hughes, D. A., 1 Ion 2006, Yn: Pharmacoeconomics. 24, 3, t. 211-213

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

81. Cyhoeddwyd

    Public funding of drugs for orphan diseases

    Hughes, D. & Hughes, D. A., 1 Ion 2006.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

82. Cyhoeddwyd

    Rationing of drugs for rare diseases.

    Hughes, D. & Hughes, D. A., 1 Ion 2006, Yn: Pharmacoeconomics. 24, 4, t. 315-316

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

83. Cyhoeddwyd

    Improving Outcomes for People with Skin Tumours including Melanoma: Analysis of the Potential Economic Impact of the Guidance.

    Hughes, D., Linck, P., Hughes, D. A. & Edwards, R. T., 21 Chwef 2006, Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

84. Cyhoeddwyd

    Eliciting patients' preferences using a discrete choice experiment questionnaire: the role played by qualitative data in questionnaire design

    Hughes, D., Longo, M., Hughes, D. A., Myles, S. & Lisles, C., 1 Maw 2006.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

85. Cyhoeddwyd

    Population pharmacokinetic and pharmacodynamic modelling of the antimalarial chemotherapy chlorproguanil/dapsone.

    Simpson, J. A., Hughes, D., Manyando, C., Bojang, K., Aarons, L., Winstanley, P., Edwards, G., Watkins, W. A. & Ward, S., 1 Maw 2006, Yn: British Journal of Clinical Pharmacology. 61, 3, t. 289-300

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

86. Cyhoeddwyd

    Health and economic outcomes: Why compliance matters

    Hughes, D. & Hughes, D. A., 1 Ebr 2006.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

87. Cyhoeddwyd

    Physchiatrist prescribing preferences and attitudes toward promotion

    Hughes, D., Menkes, D., Davies, R. & Hughes, D. A., 1 Ebr 2006.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

88. Cyhoeddwyd

    Rationing of drugs for rare diseases

    Hughes, D. & Hughes, D. A., 1 Ebr 2006.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

89. Cyhoeddwyd

    Back to basics: what is the relationship between dose and duration of drug action?

    Hughes, D. & Hughes, D. A., 1 Mai 2006.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

90. Cyhoeddwyd

    Investigating factors influencing user choices to visit either general practitioners or community pharmacists in the management of minor ailments

    Hughes, D. & Hughes, D. A., 1 Mai 2006.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

91. Cyhoeddwyd

    Orphan drugs revisited: author's response.

    Hughes, D. & Hughes, D. A., 1 Mai 2006, Yn: Quarterly Journal of Medicine. 99, 5, t. 350-351

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

92. Cyhoeddwyd

    Investigating factors influencing user choices to visit either general practitioners or community pharmacists in the management of minor ailments - piloting a discrete choice experiment

    Hughes, D., Myles, S., Hughes, D. A., Longo, M. & Lisles, C., 1 Meh 2006.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

93. Cyhoeddwyd

    Prescription fee exemption research study

    Hughes, D., Myles, S., Hughes, D. A., Routledge, P. & Wales, D. F., 1 Meh 2006.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

94. Cyhoeddwyd

    Clinical and econnomic importance of completion of therapy in the treatment of LRTIs

    Hughes, D. & Hughes, D. A., 1 Medi 2006.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

95. Cyhoeddwyd

    Ultra-long acting pharmaceuticals: Do they result in better outcomes, and at an acceptable cost?

    Hughes, D. & Hughes, D. A., 1 Tach 2006.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

96. 2007
97. Cyhoeddwyd

    AWMSG criteria for appraising new medicines.

    Hughes, D. & Hughes, D. A., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

98. Cyhoeddwyd

    Adverse drug reactions in economic evaluations

    Hughes, D. & Hughes, D. A., 1 Ion 2007, Yn: Value in Health. 10, 3, t. A109

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

99. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Emtricitabine/tenofovir DF (Truvada)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

100. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report – Clofarabine (Evoltra)

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

101. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report – Co-careldopa intestinal gel (Duodopa).

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

102. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report – Darunavir (Prezista)

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

103. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report – Dasatinib (Sprycel®) Chronic, accelerated or blast phase CML.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

104. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report – Dasatinib (Sprycel®) Lymphoid blast CML and PH+ ALL.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

105. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report – Dexrazoxane (Savene)

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

106. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report – Emtricitabine (Emtriva)

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

107. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report – Idursulfase (Elaprase)

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

108. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report – Parathyroid hormone (Preotact)

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn